Business Description
SkinBioTherapeutics PLC
ISIN : GB00BF33H870
Total Employee Number:
41Description
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.33 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 4.89 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.82 | |||||
Beneish M-Score | 0.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 62.5 | |||||
3-Year EPS without NRI Growth Rate | 32.1 | |||||
3-Year FCF Growth Rate | 30.7 | |||||
3-Year Book Growth Rate | 31 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 91.2 | |||||
9-Day RSI | 78.35 | |||||
14-Day RSI | 69.77 | |||||
3-1 Month Momentum % | 17.95 | |||||
6-1 Month Momentum % | -40.26 | |||||
12-1 Month Momentum % | -31.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.14 | |||||
Quick Ratio | 4.96 | |||||
Cash Ratio | 3.99 | |||||
Days Inventory | 152.19 | |||||
Days Sales Outstanding | 43.73 | |||||
Days Payable | 112.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.2 | |||||
Shareholder Yield % | -16.55 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.96 | |||||
Operating Margin % | -20.81 | |||||
Net Margin % | -8.72 | |||||
EBITDA Margin % | 3.67 | |||||
FCF Margin % | -39.65 | |||||
OCF Margin % | -37.15 | |||||
ROE % | -6.25 | |||||
ROA % | -4.71 | |||||
ROIC % | -18.14 | |||||
3-Year ROIIC % | 27.33 | |||||
ROC (Joel Greenblatt) % | -34 | |||||
ROCE % | -4.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 61.25 | |||||
PS Ratio | 5.84 | |||||
PB Ratio | 3.95 | |||||
Price-to-Tangible-Book | 6.13 | |||||
EV-to-EBIT | -85.45 | |||||
EV-to-EBITDA | 153.98 | |||||
EV-to-Revenue | 5.66 | |||||
EV-to-Forward-Revenue | 8.79 | |||||
EV-to-FCF | -11.45 | |||||
Price-to-GF-Value | 0.19 | |||||
| Price-to-Net-Current-Asset-Value | 12.25 | |||||
| Price-to-Net-Cash | 12.25 | |||||
Earnings Yield (Greenblatt) % | -1.17 | |||||
FCF Yield % | -6.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SkinBioTherapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 5.228 | ||
| EPS (TTM) (£) | -0.001 | ||
| Beta | -2.5673 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.55 | ||
| Volatility % | 77.41 | ||
| 14-Day RSI | 69.77 | ||
| 14-Day ATR (£) | 0.009932 | ||
| 20-Day SMA (£) | 0.1065 | ||
| 12-1 Month Momentum % | -31.34 | ||
| 52-Week Range (£) | 0.05 - 0.23 | ||
| Shares Outstanding (Mil) | 259.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SkinBioTherapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SkinBioTherapeutics PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-29 09:00 | In 158 days | ||
| Annual report for 2026 | 2026-12-04 | In 132 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-12-04 | In 132 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-04 | In 132 days | ||
| Second quarter earnings conference call for 2026 | 2026-06-29 08:00 | 0.12 (+8.89%) | ||
| Second quarter earnings results for 2026 | 2026-06-08 | 0.10 (+0.00%) | ||
| General meeting for 2025 | 2025-12-29 09:00 | 0.14 (+0.00%) | ||
| Annual report for 2025 | 2025-12-05 | 0.17 (-0.75%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-12-05 | 0.17 (-0.75%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-05 | 0.17 (-0.75%) |
Show
Entries
SkinBioTherapeutics PLC Frequently Asked Questions
What is SkinBioTherapeutics PLC(LSE:SBTX)'s stock price today?
The current price of LSE:SBTX is £0.12. The 52 week high of LSE:SBTX is £0.23 and 52 week low is £0.05.
When is next earnings date of SkinBioTherapeutics PLC(LSE:SBTX)?
The next earnings date of SkinBioTherapeutics PLC(LSE:SBTX) is 2026-12-04 Est..
Does SkinBioTherapeutics PLC(LSE:SBTX) pay dividends? If so, how much?
SkinBioTherapeutics PLC(LSE:SBTX) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| SBTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Silverback Therapeutics, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm | 2021-11-12 |
Articles on SkinBioTherapeutics PLC
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers